Continuous Glucose Monitor with Siri Integration Improves Glycemic Control in Legally Blind Patients with Diabetes

Introduction: Hyperuricemia is common Type 2 diabetes at very high cardiovascular risk. Objective: Evaluate the relationship between hyperuricemia and diabetes type 2, and determine its predictive factors in this population. Patients and Methods: Retrospective study cross including 190 patients with diabetes type 2 hospitalized Service of Endocrinology of CHU Ibn Rushd Casablanca from January 2015 to December 2017. Hyperuricemia was defined as a serum uric acid concentration> 70 mg/L (men) and> 60 mg/L (women). The variables studied were the anthropometric measurements), cardiovascular factors (tobacco, hypertension, dyslipidemia), and degenerative complications (retinopathy, neuropathy, kidney failure, ischemic heart disease). The analyzes were performed by SPSS software. Results: Hyperuricemia was found in 26.5% of patients with a female predominance (76%), an average age of 55.9 years, and an average age of 12.4ans diabetes. The glycemic control was found in 84.6% of cases with mean glycated hemoglobin 8.6%. Factors associated al hyperuricemia were the blood pressure in 86% (p <0.05), dyslipidemia in 76.3% of cases (p <0.001) with hypertriglyceridemia in 48.3% of cases (p <0.02), and a hypoHDLémie 28% (p <0.001). The age, obesity, smoking, and glycemic control were associated significantly n al hyperuricemia. The research of degenerative complications of hyperuricemia has objectified renal impairment (GFR between 15 and 60ml / min) chez47% (p <0.001), it was kind of moderate in 35.8% (p <0.01) and severe in 5.1% (p <0.02), ischemic heart disease was found in 34% of cases (p <0.01). Conclusion: In our study, hyperuricemia in type 2 diabetes is common in female patients, especially with hypertension, dyslipidemia, and renal failure. Other factors such as age, obesity, smoking is not associated with hyperuricemia in type 2 diabetics.

Download Full-text

A preliminary study on diabetes self-management education and glycemic control among patients with diabetes mellitus

Journal of Nursing Education and Practice ◽

10.5430/jnep.v9n9p98 ◽

2019 ◽

Vol 9 (9) ◽

pp. 98 ◽

Cited By ~ 1

Author(s):

Kisokanth G. ◽

Indrakumar J. ◽

Prathapan S. ◽

Joseph J. ◽

Ilankoon I.M.P.S.

Keyword(s):

Diabetes Mellitus ◽

Glycemic Control ◽

Management Education ◽

Self Management ◽

Rank Test ◽

Diabetic Patients ◽

Effective Measure ◽

Before And After ◽

Patients With Diabetes ◽

Preliminary Study

This study was aimed to assess the effectiveness of diabetes self-management education (DSME) in the improvement of glycemic control among patients with type 2 Diabetes Mellitus (T2DM) in Batticaloa District, Sri Lanka. The study was a prospective interventional study and conducted as a preliminary study at medical clinic, Base hospital, Kaluwanchikudy, Batticaloa. Thirty patients with T2DM were included based on inclusion and exclusion criteria. A structured individual diabetes self-management education for 10 hours (one hour per week) was delivered to diabetic patients by the trained Nurse Health Educator. Glycosylate hemoglobin (HbA1c) was assessed as a main outcome measure and Fasting Blood Sugar (FBS), Body Mass Index (BMI) of each patient were also measured and recorded before and after the intervention. The respondent rate was 96.7% (n = 29). Majority of them were females (n = 25, 86.2%). A Wilcoxon signed rank test showed that DSME had a statistically significant reduction in HbA1c [8.60 (IQR 2.60) vs. 7.40 (IQR 2.10), p = .000] and FBS level [159.00 (IQR 77.50) vs. 134.00 (IQR 40.50), p = .002] at 3 months of intervention. The mean BMI at baseline was higher compared to 3 months of intervention [24.88 (SD ± 3.06) vs. 24.19 (SD ± 2.79)] which was statistically significant (p = .000). Majority of participants (n = 22, 75.9%) had improved their HbA1c level by ≥ 0.5% in 3 months. The diabetes self-management education is an effective measure in improving glycemic control and other clinical parameters among patients with T2DM. Thus, DSME needs to be implemented among clinic patients with T2DM for the better outcome and the preventions of complications.

Download Full-text

Diabetes and Frail Older Patients: Glycemic Control and Prescription Profile in Real Life

Pharmacy ◽

10.3390/pharmacy9030115 ◽

2021 ◽

Vol 9 (3) ◽

pp. 115

Author(s):

Anne-Sophie Mangé ◽

Arnaud Pagès ◽

Sandrine Sourdet ◽

Philippe Cestac ◽

Cécile McCambridge

Keyword(s):

Glycemic Control ◽

Older Patients ◽

Diabetes Management ◽

Real Life ◽

Cross Sectional ◽

Glucose Lowering ◽

Frailty Status ◽

Frail Patients ◽

Patients With Diabetes ◽

Hba1c Target

(1) Background: The latest recommendations for diabetes management adapt the objectives of glycemic control to the frailty profile in older patients. The purpose of this study was to evaluate the proportion of older patients with diabetes whose treatment deviates from the recommendations. (2) Methods: This cross-sectional observational study was conducted in older adults with known diabetes who underwent an outpatient frailty assessment in 2016. Glycated hemoglobin (HbA1c) target is between 6% and 7% for nonfrail patients and between 7% and 8% for frail patients. Frailty was evaluated using the Fried criteria. Prescriptions of glucose-lowering drugs were analyzed based on explicit and implicit criteria. (3) Results: Of 110 people with diabetes with an average age of 81.7 years, 67.3% were frail. They had a mean HbA1c of 7.11%. Of these patients, 60.9% had at least one drug therapy problem in their diabetes management and 40.9% were potentially overtreated. The HbA1c distribution in relation to the targets varied depending on frailty status (p < 0.002), with overly strict control in frail patients (p < 0.001). (4) Conclusions: Glycemic control does not seem to be routinely adjusted to the health of frail patients. Several factors can lead to overtreatment of these patients.

Download Full-text

Lack of association between either outpatient or inpatient glycemic control and COVID-19 illness severity or mortality in patients with diabetes

BMJ Open Diabetes Research & Care ◽

10.1136/bmjdrc-2021-002203 ◽

2021 ◽

Vol 9 (1) ◽

pp. e002203

Author(s):

Paras B Mehta ◽

Michael A Kohn ◽

Suneil K Koliwad ◽

Robert J Rushakoff

Keyword(s):

Glycemic Control ◽

Insulin Treatment ◽

Insulin Level ◽

Illness Severity ◽

Icu Admission ◽

Patients With Diabetes ◽

Design And Methods ◽

Insulin Use ◽

Average Glucose ◽

Ventilator Requirement

IntroductionTo evaluate whether outpatient insulin treatment, hemoglobin A1c (HbA1c), glucose on admission, or glycemic control during hospitalization is associated with SARS-CoV-2 (COVID-19) illness severity or mortality in hospitalized patients with diabetes mellitus (DM) in a geographical region with low COVID-19 prevalence.Research design and methodsA single-center retrospective study of patients hospitalized with COVID-19 from January 1 through August 31, 2020 to evaluate whether outpatient insulin use, HbA1c, glucose on admission, or average glucose during admission was associated with intensive care unit (ICU) admission, mechanical ventilation (ventilator) requirement, or mortality.ResultsAmong 111 patients with DM, 48 (43.2%) were on outpatient insulin and the average HbA1c was 8.1% (65 mmol/mol). The average glucose on admission was 187.0±102.94 mg/dL and the average glucose during hospitalization was 173.4±39.8 mg/dL. Use of outpatient insulin, level of HbA1c, glucose on admission, or average glucose during hospitalization was not associated with ICU admission, ventilator requirement, or mortality among patients with COVID-19 and DM.ConclusionsOur findings in a region with relatively low COVID-19 prevalence suggest that neither outpatient glycemic control, glucose on admission, or inpatient glycemic control is predictive of illness severity or mortality in patients with DM hospitalized with COVID-19.

Download Full-text